仁度生物
(688193)
| 流通市值：22.03亿 | | | 总市值：22.03亿 |
| 流通股本：4006.99万 | | | 总股本：4006.99万 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 42,078,944.06 | 161,942,569.09 | 119,154,895.95 | 81,242,468.3 |
| 营业收入 | 42,078,944.06 | 161,942,569.09 | 119,154,895.95 | 81,242,468.3 |
| 二、营业总成本 | 40,002,823.79 | 180,039,662.39 | 131,604,403.33 | 88,783,400.31 |
| 营业成本 | 10,012,421.26 | 35,561,286.71 | 26,511,727.4 | 17,680,776.11 |
| 税金及附加 | 600,013.72 | 2,095,063.47 | 1,503,703.15 | 931,482 |
| 销售费用 | 16,862,704.56 | 77,700,093.58 | 58,192,657.32 | 40,134,358.55 |
| 管理费用 | 5,814,291.51 | 31,334,705.58 | 20,802,399.82 | 14,156,285.32 |
| 研发费用 | 6,687,643.81 | 34,590,668.4 | 25,647,407.63 | 16,679,648.87 |
| 财务费用 | 25,748.94 | -1,242,155.35 | -1,053,491.99 | -799,150.54 |
| 其中:利息费用 | 49,666.83 | 236,404.11 | 194,224.74 | 112,121.27 |
| 其中:利息收入 | 73,374.2 | 1,604,758.94 | 1,274,417.87 | 963,151.25 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 247,357.32 | 3,624,066.22 | 4,249,405.63 | 1,985,862.02 |
| 加:投资收益 | 3,393,178.06 | 10,106,748.06 | 6,431,926.46 | 4,904,494.32 |
| 资产处置收益 | 14,898.14 | -386,313.64 | -386,313.64 | 7,322.72 |
| 资产减值损失(新) | -394,691.92 | -1,947,447.67 | -1,351,284.39 | -905,130 |
| 信用减值损失(新) | -222,448.07 | 12,055,316.99 | 7,237,872.96 | -266,329.84 |
| 其他收益 | 660,233.5 | 5,068,756.28 | 3,795,065.18 | 2,690,562.37 |
| 四、营业利润 | 5,774,647.3 | 10,424,032.94 | 7,527,164.82 | 875,849.58 |
| 加:营业外收入 | 14,690.27 | 53,620.87 | 53,620.87 | 53,089.9 |
| 减:营业外支出 | 319,033.35 | 258,610.28 | 238,885.36 | 164,556.17 |
| 五、利润总额 | 5,470,304.22 | 10,219,043.53 | 7,341,900.33 | 764,383.31 |
| 减:所得税费用 | 474,900.3 | 131,657.33 | 328,178.76 | -1,273,582.67 |
| 六、净利润 | 4,995,403.92 | 10,087,386.2 | 7,013,721.57 | 2,037,965.98 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 4,995,403.92 | 10,087,386.2 | 7,013,721.57 | 2,037,965.98 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 4,995,403.92 | 10,087,386.2 | 7,013,721.57 | 2,037,965.98 |
| 扣除非经常损益后的净利润 | 2,146,977.05 | -11,708,894.3 | -7,724,813.05 | -4,282,814.89 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.12 | 0.26 | 0.18 | 0.06 |
| (二)稀释每股收益 | 0.12 | 0.26 | 0.18 | 0.06 |
| 八、其他综合收益 | -521,780.89 | -812,996.32 | -428,869.26 | -156,621.24 |
| 归属于母公司股东的其他综合收益 | -521,780.89 | -812,996.32 | -428,869.26 | -156,621.24 |
| 九、综合收益总额 | 4,473,623.03 | 9,274,389.88 | 6,584,852.31 | 1,881,344.74 |
| 归属于母公司股东的综合收益总额 | 4,473,623.03 | 9,274,389.88 | 6,584,852.31 | 1,881,344.74 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |